Evoke Pharma Q3 EPS $(0.06) Beats $(0.07) Estimate, Sales $930.45K Beat $380.00K Estimate
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 25 percent increase over losses of $(0.08) per share from the
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Evoke Pharma, EVERSANA Reports Findings From GIMOTI Market Research Study
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science
Looking Into Evoke Pharma’s Return On Capital Employed
According to Benzinga Pro data, during Q2, Evoke Pharma (NASDAQ:EVOK) posted sales of $236.63 thousand. Earnings were up 16.27%, but Evoke Pharma still reported an overall loss of $2.17 million.
